Robert G Gish Consultants

Robert G Gish Consultants Providing Medical Consulting Services to Pharma, CME Organizations, Academic and Private Institutions

The "Treat All" approach continues to expand ✅➡️Read more here:
08/27/2026

The "Treat All" approach continues to expand ✅

➡️Read more here:

Spontaneous hepatitis B surface antigen (HBsAg) clearance is rare in chronic hepatitis B (CHB). Identifying predictors of antiviral responses is needed.

08/26/2026

🧬 New publication!

Even if your patients are HBV vaccinated: check a full HBV acute panel if you see acute liver injury! 🚨

Our new study, “Acute hepatitis B in the vaccination era: Predictors of functional cure and chronicity,” highlights an important clinical reminder: acute HBV still occurs in the vaccination era and may have a higher-than-expected risk of progressing to chronic infection.

In this retrospective cohort of 78 adults with acute HBV:
🔹 65.3% achieved functional cure
🔹 34.6% progressed to chronic HBV
🔹 Diabetes was strongly associated with progression to chronic infection
🔹 Higher ALT levels were associated with functional cure

These findings reinforce the importance of recognizing acute HBV, obtaining comprehensive HBV serologies, and ensuring appropriate follow-up—even in an era of widespread vaccination

📖 Read the full article: https://dx.doi.org/10.4254/wjh.124108

Azure WAF

I’m pleased to share my recent webinar on HepQuant Duo, an innovative tool that provides a more comprehensive assessment...
08/25/2026

I’m pleased to share my recent webinar on HepQuant Duo, an innovative tool that provides a more comprehensive assessment of liver function and disease severity

As we continue moving toward more personalized, data-driven care in chronic liver disease, tools that help us better understand functional liver health can be an important part of clinical decision-making

🎥 Watch the webinar here: https://www.youtube.com/watch?v=EvFhpZs1V6c

I hope you’ll take a look and share your thoughts!

Dr. Robert Gish discusses the HepQuant DuO® test use in the clinic....

New Article 📣I’m pleased to share our latest article in the Journal of Viral Hepatitis: “The Impact of Chronic Hepatitis...
08/18/2026

New Article 📣

I’m pleased to share our latest article in the Journal of Viral Hepatitis: “The Impact of Chronic Hepatitis D Virus Infection on Health-Related Quality of Life and Fatigue: A Real-World International Study.”

https://onlinelibrary.wiley.com/doi/10.1111/jvh.70193

This international real-world study of 211 patients demonstrates that chronic hepatitis D significantly impacts health-related quality of life and fatigue, with both worsening as disease severity progresses

🔬 Very similar to hepatitis B, delta virus impacts individuals' quality of life and as another indication to take the treat-all approach

In another manuscript we have talked about improvement of quality of life with treatment 📈

The message is clear: treating hepatitis D is not only about preventing cirrhosis, liver cancer, liver transplantation, and death—it is also about helping people live better today. 🩺🌎

As little is known about the disease burden of chronic hepatitis D virus (HDV) infection, this study examined health-related quality of life (HRQoL) and fatigue at different disease stages. This was ...

📢 FREE Hepatitis B Educational Webinar – Save Your Spot! 🩺💙Join me, Dr. George Yanni and Dr. Paul Martin on Thursday, Au...
08/05/2026

📢 FREE Hepatitis B Educational Webinar – Save Your Spot! 🩺💙

Join me, Dr. George Yanni and Dr. Paul Martin on Thursday, August 20, 2026, from 6:00–7:00 PM Pacific for a FREE educational webinar on Hepatitis B (HBV)

During this interactive roundtable discussion, we will explore:
🦠 Understanding hepatitis B
🩺 Risks of chronic HBV, including cirrhosis and liver cancer
💡 Current management and patient care
❓ Live expert discussion and insights

✅ Registration is FREE! Register today and invite your friends, family, colleagues, and anyone who may benefit from this important conversation

https://www.liverhealthfoundations.org/hep-b-registration

I am excited to share our newest publication! 📖🧬Our latest article highlights an important shift in how we think about h...
08/04/2026

I am excited to share our newest publication! 📖🧬

Our latest article highlights an important shift in how we think about hepatitis delta (HDV) treatment

The reason to treat everyone with delta hepatitis extends far beyond preventing cirrhosis, liver cancer, liver transplantation, and death. Improving quality of life is just as important. This reflects the same evolution we're seeing with the "treat all" approach for hepatitis B—moving beyond simply preventing complications to improving overall health and well-being for every person living with chronic viral hepatitis

As our understanding of HDV continues to advance, it's time for treatment strategies to evolve as well

📄 Read the full article here:
http://dx.doi.org/10.1111/jvh.70193

As little is known about the disease burden of chronic hepatitis D virus (HDV) infection, this study examined health-related quality of life (HRQoL) and fatigue at different disease stages. This was ...

07/28/2026

This year’s theme, “Hepatitis: Let’s Break It Down,” calls for the removing the barriers in the way of saving people's lives.

🌍Today is World Hepatitis Day🌍Today is an opportunity to recognize both how far we've come and how much work remains💉 We...
07/28/2026

🌍Today is World Hepatitis Day🌍

Today is an opportunity to recognize both how far we've come and how much work remains

💉 We have the knowledge and tools to prevent hepatitis B through vaccination, cure hepatitis C, and effectively treat hepatitis B and hepatitis D. Yet millions of people around the world remain undiagnosed, untreated, or without access to the care they need. Too many continue to develop cirrhosis, liver failure, and liver cancer from diseases that can often be prevented or managed.

🩺 This is why universal screening, timely diagnosis, linkage to care, and equitable access to treatment are so important. We must continue to educate healthcare providers, expand testing for hepatitis B, hepatitis C, and hepatitis D, improve surveillance for hepatocellular carcinoma, and accelerate research toward finite cures for hepatitis B and better therapies for hepatitis D.

🤝 On this World Hepatitis Day, let's recommit to breaking down the barriers that prevent people from receiving life-saving care. By working together—patients, providers, researchers, advocates, industry, and policymakers—we can move closer to the WHO goal of eliminating viral hepatitis as a public health threat.

✨ Every person tested is an opportunity to save a life. Every patient linked to care brings us one step closer to elimination

🌟 Together, we can prevent hepatitis, expand access to care, reduce liver cancer, and work toward a future free from viral hepatitis

🎙️ New Podcast!I had the opportunity to join Gastroenterology Learning Network to discuss some of the latest advances in...
07/27/2026

🎙️ New Podcast!

I had the opportunity to join Gastroenterology Learning Network to discuss some of the latest advances in the management of hepatitis B and hepatitis D

In this episode, we cover:
🦠 The recent approval of bulevirtide for hepatitis D
🔬 Why universal HDV screening for everyone living with chronic hepatitis B is so important
💊 Practical treatment considerations for HBV/HDV coinfection
🌍 How earlier diagnosis and treatment can help improve patient outcomes and move us closer to hepatitis elimination goals.

🎧 Listen here: https://www.hmpgloballearningnetwork.com/site/gastro/podcasts/robert-gish-md-advances-managing-hepatitis-b-and-d

Dr Gish discusses the recent approval of bulevirtide for the treatment of hepatitis D, and the importance of screening and monitoring patients with hepatitis B for hepatitis D to enable effective treatment.

Address

San Diego, CA

Alerts

Be the first to know and let us send you an email when Robert G Gish Consultants posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share